B. Askew

发表

Non-Peptide αvβ3 Antagonists. Part 4: Potent and Orally Bioavailable Chain-Shortened RGD Mimetics

P. Coleman, C. Leu, S. Rodan, 2002 .

11β-Hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases

C. Fotsch, J. Chen, B. Askew, 2005 .

Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis.

P. Coleman, C. Leu, G. Wesolowski, 2004, Journal of medicinal chemistry.

Flow cytometric measurement of kinetic and equilibrium binding parameters of arginine-glycine-aspartic acid ligands in binding to glycoprotein IIb/IIIa on platelets.

P. A. McQueney, R. Gould, G. Hartman, 1997, Cytometry.

Molecular recognition with convergent functional groups. VII. Energetics of adenine binding with model receptors

J. Rebek, P. Ballester, Kyu‐Sung Jeong, 1989 .

Molecular recognition: hydrogen bonding and stacking interactions stabilize a model for nucleic acid structure

J. Rebek, P. Ballester, B. Askew, 1987 .

Molecular Recognition with Convergent Functional Groups. Part 7. Energetics of Adenine Binding with Model Receptors

J. Rebek, P. Ballester, Kyu‐Sung Jeong, 1989 .

Convergent functional groups. 4. Recognition and transport of amino acids across a liquid membrane

K. Parris, J. Rebek, B. Askew, 1987 .

Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.

J. Baldwin, R. Gould, G. Hartman, 1997, The Journal of pharmacology and experimental therapeutics.

Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.

T. Prueksaritanont, T. Hamill, J. A. Naue, 1997, Drug metabolism and disposition: the biological fate of chemicals.

The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors.

Jiandong Zhang, R. Hungate, Meredith Williams, 2007, Bioorganic & medicinal chemistry letters.

Nonpeptide glycoprotein IIb/IIIa inhibitors. 13. design and synthesis of an orally active pyrazolopiperazinone nonpeptide fibrinogen receptor antagonist

P. Anderson, J. Baldwin, R. Gould, 1997 .

Non-peptide glycoprotein IIb/IIIa inhibitors. 6. Design and synthesis of rigid, centrally constrained non-peptide fibrinogen receptor antagonists

R. Gould, D. Claremon, C. A. Hunt, 1995 .

Convergent functional groups. 3. A molecular cleft recognizes substrates of complementary size, shape, and functionality

J. Rebek, F. Lin, B. Askew, 1987 .

A new class of bradykinin 1 receptor antagonists containing the piperidine acetic acid tetralin core.

G. Biddlecome, C. Fotsch, Kevin C Yang, 2006, Bioorganic & medicinal chemistry letters.

SAR and evaluation of novel 5H-benzo[c][1,8]naphthyridin-6-one analogs as Aurora kinase inhibitors.

Xuliang Jiang, B. Huck, H. Tian, 2013, Bioorganic & medicinal chemistry letters.

Discovery of dihydroquinoxalinone acetamides containing bicyclic amines as potent Bradykinin B1 receptor antagonists.

S. Hitchcock, L. Arik, V. Viswanadhan, 2008, Bioorganic & medicinal chemistry letters.

Discovery of Evobrutinib: An Oral, Potent and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.

M. Camps, A. Follis, B. Huck, 2019, Journal of medicinal chemistry.

Potent nonpeptide antagonists of the bradykinin B1 receptor: structure-activity relationship studies with novel diaminochroman carboxamides.

Ming Huang, Hong Sun, Eileen Johnson, 2007, Journal of medicinal chemistry.

Molecular recognition with convergent functional groups. VI: Synthetic and structural studies with a model receptor for nucleic acid components

Julius Rebek, Pablo Ballester, K. Parris, 1989 .

Convergent functional groups: synthetic and structural studies

K. Parris, J. Rebek, N. Islam, 1985 .

Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.

J. Baldwin, T. Prueksaritanont, R. Gould, 1997, Journal of medicinal chemistry.

Molecular recognition new shapes for asymmetric microenvironments

Maria J. Doa, J. Rebek, P. Ballester, 1987 .

Convergent functional groups. 5. Ternary complexes in the molecular recognition of .beta.-arylethylamines

J. Rebek, P. Ballester, A. Costero, 1988 .

Molecular recognition: Watson-Crick, Hoogsteen, and bifurcated hydrogen bonding in a model for adenine recognition

J. Rebek, P. Ballester, A. Costero, 1987 .

Convergent Functional Groups. Part 5. Ternary Complexes in the Molecular Recognition of β‐Arylethylamines.

J. Rebek, P. Ballester, A. Costero, 1988 .

Synthetic receptors: size and shape recognition within a molecular cleft

J. Rebek, N. Islam, B. Askew, 1985 .

Molecular Recognition: Watson-Crick, Hoogsteen, and Bifurcated Hydrogen Bonding in a Model for Adenine Recognition.

J. Rebek, P. Ballester, A. Costero, 1988 .

Stereoelectronic effects and the active site of the serine proteases

J. Rebek, R. Duff, Jeffrey B. Huff, 1988 .

Aryl sulfones as novel bradykinin B1 receptor antagonists for treatment of chronic pain.

L. Arik, R. Hungate, G. Biddlecome, 2008, Bioorganic & medicinal chemistry letters.

Aryl sulfonamides containing tetralin allylic amines as potent and selective bradykinin B1 receptor antagonists.

L. Arik, R. Hungate, G. Biddlecome, 2010, Bioorganic & medicinal chemistry letters.

Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity.

L. Arik, E. Laird, V. Viswanadhan, 2007, Journal of medicinal chemistry.

Molecular Recognition: Hydrogen Bonding and Stacking Interactions Stabilize a Model for Nucleic Acid Structure.

J. Rebek, P. Ballester, B. Askew, 1987 .

Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury.

R. Gould, G. Hartman, J. Lynch, 1997, Circulation.

Ocular Distribution and Pharmacodynamics of SF0166, a Topically Administered αvβ3 Integrin Antagonist, for the Treatment of Retinal Diseases

D. Edwards, B. Askew, T. Furuya, 2018, The Journal of Pharmacology and Experimental Therapeutics.

The design and synthesis of macrobicyclic hosts featuring convergent functional groups.

B. Askew, 1991 .

Ocular Distribution and Pharmacodynamics of SF0166, a Topically Administered αvβ3 Integrin Antagonist, for the Treatment of Retinal Diseases

D. Edwards, B. Askew, T. Furuya, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Nonpeptide αvβ3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone

C. Leu, S. Rodan, G. Rodan, 2004 .